Cynthia A. Stuenkel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cynthia A. Stuenkel has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Richard J Santen
University of Virginia Health System, Division of Endocrinology and Metabolism, Charlottesville, VA, USA
1 shared publication
Latest Publications
- 19 October 2020
- Published by Taylor & Francis in Climacteric
- Vol. 24 (1) , 11-18
Compounded bioidentical menopausal hormone therapy – a physician perspective
One of the defining moments of the 80-year evolution of menopausal hormone therapy (MHT) was the 2002 reveal of the initial results of the combined hormone therapy arm of the Women’s Health Initiative (WHI) clinical trial. The exodus from regulatory approved MHT was prompt and profound and accompanied by a rapid acceleration of the compounding pharmacy ‘bioidentical’ hormone therapy industry. Compounders had recruited prescribers and promoted compounded bioidentical hormone therapy (cBHT) well before the WHI, yet the startling results provided a catalyst that enabled a leap in production of compounded hormones that were variably regulated, basically unstudied, and inconsistently labeled. In this review, the story of the rise of cBHT and the regulatory double standard is eclipsed only by the 2020 findings and recommendations of the US National Academies of Science, Engineering, and Medicine. Their investigation, commissioned by the US Food and Drug Administration, was tasked to: provide an evidence-based summary of the clinical utility of cBHT; evaluate whether the evidence of safety and efficacy supports the use of cBHT; and identify patient populations that might need cBHT in lieu of an approved drug product. Their conclusions are consistent with sound science and their recommendations are in harmony with global menopause societies.
- 19 October 2020
- Published by Taylor & Francis in Climacteric
- Vol. 24 (1) , 11-18
Compounded bioidentical menopausal hormone therapy – a physician perspective
One of the defining moments of the 80-year evolution of menopausal hormone therapy (MHT) was the 2002 reveal of the initial results of the combined hormone therapy arm of the Women’s Health Initiative (WHI) clinical trial. The exodus from regulatory approved MHT was prompt and profound and accompanied by a rapid acceleration of the compounding pharmacy ‘bioidentical’ hormone therapy industry. Compounders had recruited prescribers and promoted compounded bioidentical hormone therapy (cBHT) well before the WHI, yet the startling results provided a catalyst that enabled a leap in production of compounded hormones that were variably regulated, basically unstudied, and inconsistently labeled. In this review, the story of the rise of cBHT and the regulatory double standard is eclipsed only by the 2020 findings and recommendations of the US National Academies of Science, Engineering, and Medicine. Their investigation, commissioned by the US Food and Drug Administration, was tasked to: provide an evidence-based summary of the clinical utility of cBHT; evaluate whether the evidence of safety and efficacy supports the use of cBHT; and identify patient populations that might need cBHT in lieu of an approved drug product. Their conclusions are consistent with sound science and their recommendations are in harmony with global menopause societies.
- 4 February 2019
- Published by Taylor & Francis in Climacteric
- Vol. 22 (2) , 133-139
Do we have new preventive strategies for optimizing cardiovascular health in women?
Over the past decades, progress in efforts to reduce cardiovascular morbidity and mortality has been achieved, although a disturbing trend for stagnation of cardiovascular mortality rates among younger women compared with those in younger men has been identified. While the menopause transition has traditionally offered an unequivocal opportunity to assess cardiovascular risk and counsel women to adopt preventive strategies, the veritable 'window of opportunity', usually applied to the concept of timing the initiation of menopausal hormone therapy, must be opened much wider to encompass younger women including those who have experienced adverse events during pregnancy, treatment for breast cancer, and premature menopause. Collaborative efforts by a number of expert medical groups provide encouragement and justification for an aggressive approach to identify and modify cardiovascular risk earlier in younger women, starting at age 20 years. Quantifying cardiovascular risk with country and population-specific risk calculators can be helpful to validate perception of risk and encourage preventive recommendations. Adherence to established guidelines for lifestyle measures (smoking cessation, healthful eating habits, enhanced physical activity, and weight control) along with treatment of traditional risk factors - hypertension, glucose intolerance, and dyslipidemia - provides a sound basis for prevention of cardiovascular disease in women.
- 4 February 2019
- Published by Taylor & Francis in Climacteric
- Vol. 22 (2) , 133-139
Do we have new preventive strategies for optimizing cardiovascular health in women?
Over the past decades, progress in efforts to reduce cardiovascular morbidity and mortality has been achieved, although a disturbing trend for stagnation of cardiovascular mortality rates among younger women compared with those in younger men has been identified. While the menopause transition has traditionally offered an unequivocal opportunity to assess cardiovascular risk and counsel women to adopt preventive strategies, the veritable 'window of opportunity', usually applied to the concept of timing the initiation of menopausal hormone therapy, must be opened much wider to encompass younger women including those who have experienced adverse events during pregnancy, treatment for breast cancer, and premature menopause. Collaborative efforts by a number of expert medical groups provide encouragement and justification for an aggressive approach to identify and modify cardiovascular risk earlier in younger women, starting at age 20 years. Quantifying cardiovascular risk with country and population-specific risk calculators can be helpful to validate perception of risk and encourage preventive recommendations. Adherence to established guidelines for lifestyle measures (smoking cessation, healthful eating habits, enhanced physical activity, and weight control) along with treatment of traditional risk factors - hypertension, glucose intolerance, and dyslipidemia - provides a sound basis for prevention of cardiovascular disease in women.
- 1 September 2018
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 61 (3) , 433-446
Vasomotor and Related Menopause Symptoms
Vasomotor symptoms are the most common manifestation of the menopause transition and postmenopausal phases of reproductive life. They interfere not only in quality of life, but also contribute to sleep and mood disturbances that potentially compromise home and work effectiveness. Treatment options include hormone therapy (HT), nonhormonal prescription drugs, mind body and behavior therapies, and over-the-counter preparations. Evidence confirms that HT is the most effective option. The initial reticence to prescribe HT immediately following publication of the Women’s Health Initiative has been replaced by clear guidelines for confidently identifying women for whom this therapy will be safe.
- 1 September 2018
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 61 (3) , 433-446
Vasomotor and Related Menopause Symptoms
Vasomotor symptoms are the most common manifestation of the menopause transition and postmenopausal phases of reproductive life. They interfere not only in quality of life, but also contribute to sleep and mood disturbances that potentially compromise home and work effectiveness. Treatment options include hormone therapy (HT), nonhormonal prescription drugs, mind body and behavior therapies, and over-the-counter preparations. Evidence confirms that HT is the most effective option. The initial reticence to prescribe HT immediately following publication of the Women’s Health Initiative has been replaced by clear guidelines for confidently identifying women for whom this therapy will be safe.
- 2 January 2017
- Published by Taylor & Francis in Climacteric
- Vol. 20 (1) , 11-21
Menopause, hormone therapy and diabetes
Over the past three decades, the prevalence of diabetes has increased four-fold. Coupled with the global obesity epidemic and aging of the world’s population, a perfect metabolic storm is brewing. The influence of menopause and exogenous estrogen and progestogens must be included in this equation. In this review, criteria for diagnosing diabetes and recommendations for screening are described. The reported effects of menopause on diabetes risk in healthy women are reviewed as well as the relationship between established diabetes and the timing of menopause. The effects of menopausal hormone therapies (MHT) on glucose control in women with diabetes and the effect of MHT on diabetes risk in menopausal women without diabetes are described. Evidence-based strategies to prevent diabetes in midlife women are highlighted. The augmenting effect of diabetes on chronic health concerns of aging women, such as cardiovascular disease, osteoporosis, and cancer, along with current recommendations for screening and prevention are presented. Given the current demographics of today’s world, the content of this review may apply to as many as one-third of the average practitioner’s postmenopausal patient population.
- 2 January 2017
- Published by Taylor & Francis in Climacteric
- Vol. 20 (1) , 11-21
Menopause, hormone therapy and diabetes
Over the past three decades, the prevalence of diabetes has increased four-fold. Coupled with the global obesity epidemic and aging of the world’s population, a perfect metabolic storm is brewing. The influence of menopause and exogenous estrogen and progestogens must be included in this equation. In this review, criteria for diagnosing diabetes and recommendations for screening are described. The reported effects of menopause on diabetes risk in healthy women are reviewed as well as the relationship between established diabetes and the timing of menopause. The effects of menopausal hormone therapies (MHT) on glucose control in women with diabetes and the effect of MHT on diabetes risk in menopausal women without diabetes are described. Evidence-based strategies to prevent diabetes in midlife women are highlighted. The augmenting effect of diabetes on chronic health concerns of aging women, such as cardiovascular disease, osteoporosis, and cancer, along with current recommendations for screening and prevention are presented. Given the current demographics of today’s world, the content of this review may apply to as many as one-third of the average practitioner’s postmenopausal patient population.
- Open Access
- 1 March 2016
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 22 (1) , 6-8
An introduction to the Endocrine Society Clinical Practice Guideline on treatment of symptoms of the menopause
Treatment of symptoms of menopause remains a challenge for many health care practitioners. In an effort to facilitate this process, the Endocrine Society convened an international Task Force of menopause experts to review the relevant clinical evidence and formulate practical recommendations for relieving the most common menopausal symptoms. The result is a comprehensive evidence-based guideline, which emphasizes an individualized approach to alleviate bothersome vasomotor symptoms and those related to postmenopausal changes of the vagina and urinary tract. Therapies including estrogen, either alone or in combination with progestogen or bazedoxifene, tibolone, antidepressants, gabapentin, as well as complementary approaches are discussed. In this commentary, the chairs of the Task Force highlight the organization and content of the guideline and the processes involved in its development.
- 1 March 2016
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 22 (1) , 6-8
Open AccessAn introduction to the Endocrine Society Clinical Practice Guideline on treatment of symptoms of the menopause
Treatment of symptoms of menopause remains a challenge for many health care practitioners. In an effort to facilitate this process, the Endocrine Society convened an international Task Force of menopause experts to review the relevant clinical evidence and formulate practical recommendations for relieving the most common menopausal symptoms. The result is a comprehensive evidence-based guideline, which emphasizes an individualized approach to alleviate bothersome vasomotor symptoms and those related to postmenopausal changes of the vagina and urinary tract. Therapies including estrogen, either alone or in combination with progestogen or bazedoxifene, tibolone, antidepressants, gabapentin, as well as complementary approaches are discussed. In this commentary, the chairs of the Task Force highlight the organization and content of the guideline and the processes involved in its development.
- 1 September 2015
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 44 (3) , 565-585
Menopausal Hormone Therapy
- 1 September 2015
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 44 (3) , 565-585
Menopausal Hormone Therapy